David Bellnier

David Bellnier

PhD

Special Interests:

Photodynamic Therapy: Basic and Translational Research

About Me

Biography:

Dr. David A. Bellnier joined the staff of Roswell Park Comprehensive Cancer Center (Roswell Park) and is currently an Assistant Member (Clinical Research) in the Department of Cell Stress Biology, a member of the Photodynamic Therapy (PDT) Center, a member of the Biophysical Therapies Program and Assistant Professor of Oncology at the State University of New York at Buffalo. Dr. Bellnier earned his doctoral degree in Radiation Biology at SUNY Buffalo, Roswell Park Division, in 1982 and did postdoctoral training in Urology Research at Massachusetts General Hospital in Boston, MA and at the Center for Advanced Laser Research, Baylor University Medical Center in Dallas, TX. Dr. Bellnier’s research focuses primarily on the use of photodynamic therapy, as a monotherapy or in a combination therapy setting, to treat malignant tumors; he also has a large number of collaborations in other fields, including: pharmacologic intervention in moderate-severe burn wounds in rodents; pharmacologic potentiation of local hyperthermia to control solid tumors; pharmacologic protection of normal, and not tumor, tissues following chemoradiation therapy; and the use of PDT to control MRSA. Dr. Bellnier’s research programs take place in the multidisciplinary, highly interactive environments of the PDT Center and the Biophysical Therapies Program, and in collaboration with colleagues throughout the Institute and other Universities/Hospitals.


Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Department of Cell Stress Biology

Research

Research Overview:

Dr. David A. Bellnier joined the staff of Roswell Park Cancer Institute (RPCI) and is currently an Assistant Member (Clinical Research) in the Department of Cell Stress Biology, a member of the Photodynamic Therapy (PDT) Center, a member of the Biophysical Therapies Program and Assistant Professor of Oncology at the State University of New York at Buffalo. Dr. Bellnier earned his doctoral degree in Radiation Biology at SUNY Buffalo, Roswell Park Division, in 1982 and did postdoctoral training in Urology Research at Massachusetts General Hospital in Boston, MA and at the Center for Advanced Laser Research, Baylor University Medical Center in Dallas, TX.

Dr. Bellnier’s research focuses primarily on the use of photodynamic therapy, as a monotherapy or in a combination therapy setting, to treat malignant tumors; he also has a large number of collaborations in other fields, including: pharmacologic intervention in moderate-severe burn wounds in rodents; pharmacologic potentiation of local hyperthermia to control solid tumors; pharmacologic protection of normal, and not tumor, tissues following chemoradiation therapy; and the use of PDT to control MRSA. Dr. Bellnier’s research programs take place in the multidisciplinary, highly interactive environments of the PDT Center and the Biophysical Therapies Program, and in collaboration with colleagues throughout the Institute and other Universities/Hospitals.


Publications

Seshadri M, Bellnier DA. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo. Photochemistry and photobiology 2009; 85(1):50-56

Zheng X, Henderson BW, Bellnier DA, Jackson J, Batt C, Missert JR, Baumann H, Tracy E, Chen Y, Pandey SK, Morgan J, Pandey RK. Conjugation of 2-(1'-hexyloxyethyl)-2-devinylpyropheophorbide-a (HPPH) to carbohydrates changes its subcellular distribution and enhances photodynamic activity in vivo.Journal of medicinal chemistry 2009; 52(14):4306-4318

Seshadri M, Bellnier DA, Cheney RT. Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.International journal of radiation oncology, biology, physics 2008; 72(4):1198-1207

Seshadri M, Bellnier DA, Vaughan LA, Spernyak JA, Mazurchuk R, Foster TH, Henderson BW. Light delivery over extended time periods enhances the effectiveness of photodynamic therapy. Clinical cancer research 2008;14(9):2796-2805

Pandey SK, Dougherty TJ, Henderson BW, Oseroff AR, Bellnier DA, Shibata M, Liu TH, Missert JR, Morgan J, Zheng X, Pandey RK. Purpurinimide carbohydrate conjugates: effect of the position of the carbohydrate moiety in photosensitizing efficacy. Molecular pharmaceutics 2007; 4(3):448-464

Seshadri M, Spernyak JA, Maiery PG, Cheney RT, Mazurchuk R, Bellnier DA.Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome. Neoplasia (New York, N.Y.) 2007; 9(2):128-135

Marrero A, Becker T, Sunar U, Morgan J, Bellnier D. Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses. Photochemistry and photobiology 2011; 87(4):910-919

Seshadri M, Maier PG, Bellnier DA. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) improves the antitumor activity and shortens treatment time associated with Photochlor (2-[l-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)-sensitized photodynamic therapy in vivo.Proceedings of the American Association for Cancer Research Annual Meeting2007; 48:1137

Seshadri M, Maier PG, Vaughan LA, Cheney RT, Bellnier DA. Influence of tumor microenvironment on the vascularity and response of murine fibrosarcomas to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA): ectopic versus orthotopic tumors. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:1098

Seshadri M, Spernyak JA, Mazurchuk R, Vaughan LA, Bellnier DA, Henderson BW. Fluence rate effects on tumor oxygenation during photodynamic therapy for cancer: A BOLD (fMRI) experience. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:1292-1293

Burdelya LG, Gleiberman AS, Toshkov I, Aygun-Sunar S, Bapardekar M, Manderscheid-Kern P, Bellnier D, Krivokrysenko VI, Feinstein E, Gudkov AV.Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy.International journal of radiation oncology, biology, physics 2012; 83(1):228-234

Marrero A, Sunar U, Sands T, Oseroff A, Bellnier D. Potentiation of ALA-PDT antitumor activity in mice using topical DMXAA. Proceedings of SPIE : Biomedical Optics and Medical Imaging 2009; 7380:738071